RR001
Phase 1- Indications
- Pancreatic ductal adenocarcinoma
Company intelligence / Profile preview
Rigenerand
Medolla, Emilia-Romagna, Italyrigenerand-biotech.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Rigenerand developed cGMP-compliant products and platforms supporting the development of advanced cell and gene therapies as well as innovative biomedical devices. The company enabled preclinical to early clinical-stage programs in regenerative medicine, oncology, immunotherapy, and diagnostics through its manufacturing capabilities. No direct late-stage or commercial therapeutics reported.
- Therapeutic areas
- OtherOncology
- Modalities
- Cell therapyGene therapy3D culture biomedical devices (Device)Stem cell therapy
- Industry
- Contract Manufacturing Organization
02
Drug pipeline
1 asset03
Partnerships
RanD Srl (joint venture partner)University of Modena e Reggio Emilia (academic founding partner)Evotec SE (acquirer/investor)
Beyond the preview
Go deeper on Rigenerand.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rigenerand.